Pharmaceutical

Swissmedic approves IFINWIL for children with high-risk neuroblastoma

Swissmedic approved the registration of IFINWIL (eflornithine) as a monotherapy to treat paediatric patients with high-risk neuroblastoma,

Jul 9, 2025 - 06:00
Swissmedic approves IFINWIL for children with high-risk neuroblastoma
Swissmedic approved the registration of IFINWIL (eflornithine) as a monotherapy to treat paediatric patients with high-risk neuroblastoma,
Read the original article

Tags:

Previous Article

Research warns of rising HIV cases in Africa amid global funding cuts

Next Article

Chugai and Gero link on antibody drugs for age-related conditions

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA approves J&J’s Imaavy for generalised myasthenia gravis

FDA approves J&J’s Imaavy for generalised myasthenia gr...

May 2, 2025

House GOP inquiry over gain-of-function research targets a scientific giant

House GOP inquiry over gain-of-function research target...

Jun 22, 2023

STAT+: Former FDA official lays out how to keep patients safe from risky medical devices

STAT+: Former FDA official lays out how to keep patient...

Oct 2, 2023